Fortress Biotech Inc. (NASDAQ:FBIO) dropped 1.7% on Monday . The stock traded as low as $2.85 and last traded at $2.89, with a volume of 59,867 shares. The stock had previously closed at $2.94.

Separately, FBR & Co reaffirmed an “outperform” rating and set a $7.00 target price on shares of Fortress Biotech in a research note on Wednesday, April 6th.

The firm has a 50 day moving average of $2.76 and a 200 day moving average of $2.95. The firm’s market cap is $139.73 million.

Fortress Biotech (NASDAQ:FBIO) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.31) EPS for the quarter. On average, analysts predict that Fortress Biotech Inc. will post ($0.30) earnings per share for the current year.

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.